Text Size

Conformation-activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity

Honda T., Tajima H., Kaneko Y., Ban M., Inaba T., Takeno Y., Okamoto K., Aono H.


  • 2008
  • Bioorganic and Medicinal Chemistry Letters
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Other

  • Affiliations

    Research and Development Center, Santen Pharmaceutical Co. Ltd, 8916-16 Takayama-cho, Ikoma-shi, Nara, 630-0101, Japan; Graduate School of Materials Sciences, Nara Institute of Science and Technology, 8916-5 Takayama-cho, Ikoma-shi, Nara, 630-0192, Japan

Related Publications

Prospective natural history and clinical biomarkers of EYS-associated retinopathy in the KEYS study

Taniguchi M, Togashi Y, Yokota S, Hiraoka M, Kitahata S, Nakamura N, Yamamoto M, Mandai M, Gocho K, Toshimori M, Hirami Y, Gomi F, Kurimoto Y, Maeda A.


STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24‑Month Results of a Randomized, Double‑Masked, Vehicle‑Controlled Trial of Atropine Sulfate 0.01% and 0.03%

Korenfeld M.; Hurcikova M.; Tatsuoka K.; Cheetham J.; Kacerik M.; on behalf of the STAR Study Investigators


Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Lagreze W, Nucci P, Versteegh M, Klaver C, Barrio-Barrio J, Dahlmann-Noor A, Gomez de Liaño R, Ghorbani-Mojarrad N, Kessel L, Polling JR, Sauer A, Schuster AK, Serafino M, Villani E, Ziemssen F, Boehler YB, Capri S, Gianfrate F, Valles Callol JA, Wong O, Chen TY, Lymperopoulou C, Palaka I, Punekar Y, von Bredow D, Shi-van Wielink K.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022